Polaris Ventures

This content requires the Flash Plugin.

Founded in 1996, Polaris has backed and played a lead role in developing some of the most successful information technology and life sciences companies in the United States and Europe.

Diversification - across and within industries, and in stage - is the cornerstone of Polaris' investment strategy.

We have built an exceptional team of venture capitalists and technology executives with a broad range of investment and operating experience, the highest business standards, and a commitment to success.

Helping build first-rate management teams is a key commitment we make to the companies we back. Our on-staff team has recruited to our portfolio companies more than 50 executives for a wide range of positions without the use of an outside recruiter, from CEO to the director level.

Polaris has backed many companies that have become stars in their fields.

CONGRATULATIONS Ironwood!

Ironwood Pharmaceuticals� Initial Public Offering

CAMBRIDGE, Mass., February 16, 2010 -
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that the underwriters of its February 2, 2010 initial public offering (IPO) have exercised their over-allotment option in full on an additional 2.5 million shares of Ironwood�s Class A common stock.

Full Story



2/21/2010 Blockage breakthrough (BridgePoint Medical)

2/10/2010 Biolex Announces Locteron(R) Phase 2b Interim Results in Hepatitis C Accepted for Presentation at EASL Conference 2/1/2010 Best Mobile Startups 2010 (Emo Labs) 1/28/2010 Genocea Biosciences Appoints Paul Giannasca Vice President of Development

3/11/2010 - 3/14/2010
Association of American Veterinary Medical Colleges 2010
Liaison International
2010 AAVMC Annual Meeting and Educational Symposium
Alexandria, Virginia

3/17/2010 - 3/17/2010
2010 AMGA Annual Conference
Phytel
New Orleans, LA
Web site

3/18/2010 - 3/20/2010
American Association of Chiropractic Colleges
Liaison International
ACC-RAC Annual Conference
Las Vegas, NV

3/20/2010 - 3/23/2010
American Association of Colleges of Nursing
Liaison International
Washington, DC



2/9/2010 Phytel's Rapid Growth Attracts $14.2 Million from Strategic Investment Partners

2/1/2010 Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R) 1/25/2010 e-Rewards, Backed by Brierley+Partners, Closes on $17.6M 1/25/2010 BIND Biosciences, Inc. closes $11 M Series C financing round